Navigation Links
Scientists shine new light on inflammatory diseases
Date:3/16/2008

NEW YORK CITY, Mar. 16, 2008--Investigators at Hospital for Special Surgery have identified a new mechanism involved in the pathogenesis of inflammatory diseases such as rheumatoid arthritis. The mechanism may also shed some light on why gene therapy experiments that use adenoviruses to deliver genes to humans have run into problems. The study will appear online on March 16 in the journal Nature Immunology.

Tumor necrosis factor (TNF) is known to play a role in several important inflammatory diseases including rheumatoid arthritis. While much is known about early signaling pathways activated by TNF, little is known about delayed and chronic TNF responses. In addition, cells called macrophages produce TNF, but little is known about the effects of TNF on the macrophages themselves.

In studies using human blood cells and mice, scientists examined the responses of macrophages during a two-day period after being stimulated with TNF. They found that macrophages secreted TNF and that then the TNF activated surface receptors on the macrophages themselves, spurring the cells into a low and sustained production of a protein called interferon-beta. This protein acted synergistically with TNF signals to induce 1) sustained expression of genes encoding inflammatory molecules and 2) delayed expression of genes encoding interferon-response molecules.

The striking thing about many of these genes that came to our attention first was that there were these classic interferon response genes which had previously not been associated with TNF, said Lionel Ivashkiv, M.D., director of Basic Research at Hospital for Special Surgery, who led the study. It suggests a new mechanism by which TNF can drive and sustain inflammation.

Experiments also revealed that the so-called autocrine loop was dependant on so-called interferon-response factor 1. This was the first implication that IRF1 was linked to TNF inflammatory pathways, said Dr. Ivashkiv.

The researchers say that these findings could lead scientists to ways of preventing the bone destruction that is associated with some diseases. There is the potential to control inflammation and also to control bone destruction. This interferon response is very effective at preventing the destruction of bones, which is one of the major issues with rheumatoid arthritis, said Dr. Ivashkiv. So, what it does is sets up the next series of studies, in animal models, to try to determine whether this induction of interferon is beneficial or not.

The new research could also help explain how a patient involved in a University of Pennsylvania gene therapy experiment that used an adenovirus to deliver the gene died. Host response to adenoviral vectors is dependant on both IRF1 and TNF.

What we have described is that TNF has both pathogenic affectsit helps to sustain some of these inflammatory chemokines, but it also has a potential protective effect, because some of these interferon responses limit the amount of cell proliferation and they can also help to limit inflammation.


'/>"/>

Contact: Phyllis Fisher
fisherp@hss.edu
212-606-1197
Hospital for Special Surgery
Source:Eurekalert

Related medicine news :

1. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
2. Scientists Probe Sepsis Deadly Secrets
3. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
4. Scientists Develop Natural Protection for Stored Foods
5. Scientists detect presence of marburg virus in african fruit bats
6. Scientists Spot Brains Free Will Center
7. Scientists ID Likely Culprit in Popcorn Lung
8. Scientists explain how insulin secreting cells maintain their glucose sensitivity
9. Scripps Research scientists shed new light on how antibodies fight HIV
10. Scientists, physicians present latest findings in personalized cancer treatment and prevention
11. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... VA (PRWEB) , ... June 23, 2017 , ... ... of what is needed and will ultimately do significant harm to people with ... to everyone. , "While it leaves in place the Affordable Care Act ...
(Date:6/23/2017)... ... June 24, 2017 , ... Studies show evidence that carotenoids and ... of visual loss in these patients. , But how often do ophthalmologists and optometrists ... to patients at risk of or with early symptoms of AMD? A study ...
(Date:6/23/2017)... ... 2017 , ... Military Connection friend and veteran advocate Micaela Bensko ... Atlantic lounge. , Bensko is no stranger to the plight of the disabled. ... life to supporting our wounded veterans. A world-class photographer, her riveting photos “The Wounds ...
(Date:6/23/2017)... ... 2017 , ... The Aesthetic Channel has recently highlighted Dr. Ben Talei’s unique ... a proprietary technique that he calls the AuraLyft Facelift. The AuraLyft does ... patients can expect to look refreshed, rejuvenated, and revitalized. , Dr. Talei’s unique ...
(Date:6/23/2017)... ... June 23, 2017 , ... 21 Middle East and South Asia ... 21 leaders from government, business and civil society in 11 countries across the Middle ... fall, engaging in a transformative exchange of knowledge and ideas with the leading minds ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... 2017  StatLab Medical Products ("StatLab" or ... of diagnostic supplies for the anatomic pathology ... Company LP ("Cressey & Company"), a healthcare-focused ... investment in the Company. Cressey & Company ... selling shareholder, Prairie Capital, L.P., with certain ...
(Date:6/7/2017)... 2017  Diplomat Specialty Infusion Group, a brand of Diplomat Pharmacy, ... Iowa location. The ... features an ISO 7 cleanroom—the standard needed to compound intravenous (IV) ... level of pollutants. "Our new ... better serve our Iowa patients," said ...
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
Breaking Medicine Technology: